Here we report a critically ill patient who was cured of SARS-CoV-2 infection in Changsha, China. A 66-year-old Chinese woman, with no significant past medical history, developed severe pneumonia-like symptoms and later diagnosed as severe COVID-19 pneumonia. Within 2 months of hospitalization, the patient deteriorated to ARDS including pulmonary edema and SIRS with septic shock. When treatment schemes such as antibiotics plus corticosteroids showed diminished therapeutic value, hUCMSC therapy was compassionately prescribed under the patient’s consent of participation. After treatment, there was significant improvement in disease inflammation-related indicators such as IL-4, IL-6, and IL-10. Eventually, it confirmed the therapeutic value that hUCMSCs could dampen the cytokine storm in the critically ill COVID-19 patient and modulated the NK cells. In the continued hUCMSC treatment, gratifying results were achieved in the follow-up of the patient. The data we acquired anticipate a significant therapeutic value of MSC treatment in severe and critically ill patients with COVID-19, while further studies are needed.
【저자키워드】 COVID-19, therapy, Mesenchymal stem cells, Case report, Critically ill, 【초록키워드】 Corticosteroid, Treatment, ARDS, Severe COVID-19 pneumonia, Hospitalization, IL-6, SARS-COV-2 infection, NK cells, Antibiotics, Symptom, China, therapeutic, Patient, Septic shock, Pulmonary edema, Follow-up, IL-10, disease, IL-4, MSC, SIRS, COVID-19 patient, Critically ill patient, Chinese, past medical history, the patient, diagnosed, cured, modulated, the cytokine storm, with COVID-19, 【제목키워드】 Human, CORD, STEM, Ill,